|
Clinical trials Randomized controlled (CONSORT agreement)
Citations 11-20 of 248 total displayed.
|
Past content
(since Mar 2001):
|
- ARTICLES
A controlled trial of antidepressants in patients with Parkinson disease and depression
- M. Menza, R. D. Dobkin, H. Marin, M. H. Mark, M. Gara, S. Buyske, K. Bienfait, and A. Dicke
Neurology 2009; 72: 886-892.
[Abstract]
[Full text]
[PDF]
- ARTICLES
GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
- A. D. Goodman, H. Rossman, A. Bar-Or, A. Miller, D. H. Miller, K. Schmierer, F. Lublin, O. Khan, N. M. Bormann, M. Yang, M. A. Panzara, A. W. Sandrock For the GLANCE Investigators
Neurology 2009; 72: 806-812.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
- J. A. Cohen, P. B. Imrey, P. A. Calabresi, K. R. Edwards, T. Eickenhorst, W. L. Felton, III, E. Fisher, R. J. Fox, A. D. Goodman, C. Hara-Cleaver, G. J. Hutton, B. F. Mandell, T. F. Scott, H. Zhang, C. Apperson-Hansen, G. J. Beck, P. L. Houghtaling, M. T. Karafa, M. Stadtler For the ACT Investigators
Neurology 2009; 72: 535-541.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Plasma Aβ, homocysteine, and cognition: The Vitamin Intervention for Stroke Prevention (VISP) trial
- A. Viswanathan, S. Raj, S. M. Greenberg, M. Stampfer, S. Campbell, B. T. Hyman, and M. C. Irizarry
Neurology 2009; 72: 268-272.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study
- P. O'Connor, G. Comi, X. Montalban, J. Antel, E. W. Radue, A. de Vera, H. Pohlmann, L. Kappos For the FTY720 D2201 Study Group
Neurology 2009; 72: 73-79.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Intensive nutritional supplements can improve outcomes in stroke rehabilitation
- M. H. Rabadi, P. L. Coar, M. Lukin, M. Lesser, and J. P. Blass
Neurology 2008; 71: 1856-1861.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial
- E. J. Sorenson, A. J. Windbank, J. N. Mandrekar, W. R. Bamlet, S. H. Appel, C. Armon, P. E. Barkhaus, P. Bosch, K. Boylan, W. S. David, E. Feldman, J. Glass, L. Gutmann, J. Katz, W. King, C. A. Luciano, L. F. McCluskey, S. Nash, D. S. Newman, R. M. Pascuzzi, E. Pioro, L. J. Sams, S. Scelsa, E. P. Simpson, S. H. Subramony, E. Tiryaki, and C. A. Thornton
Neurology 2008; 71: 1770-1775.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial
- J. J. Sevigny, J. M. Ryan, C. H. van Dyck, Y. Peng, C. R. Lines, M. L. Nessly On behalf of the MK-677 Protocol 30 Study Group
Neurology 2008; 71: 1702-1708.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures
- E. Faught, G. L. Holmes, W. E. Rosenfeld, G. Novak, W. Neto, A. Greenspan, J. Schmitt, E. Yuen, S. Reines, and M. Haas
Neurology 2008; 71: 1586-1593.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
- G. Birnbaum, B. Cree, I. Altafullah, M. Zinser, and A. T. Reder
Neurology 2008; 71: 1390-1395.
[Abstract]
[Full text]
[PDF]
|
|
